Abeona Therapeutics Inc. (ABEO)
| Bid | 4.81 |
| Market Cap | 236.19M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -63.73M |
| EPS (ttm) | -1.55 |
| PE Ratio (ttm) | -3.12 |
| Forward PE | -48.35 |
| Analyst | Buy |
| Ask | 5.07 |
| Volume | 822,741 |
| Avg. Volume (20D) | 488,390 |
| Open | 4.85 |
| Previous Close | 4.85 |
| Day's Range | 4.82 - 4.96 |
| 52-Week Range | 3.05 - 7.73 |
| Beta | 1.70 |
About ABEO
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A; ABO-201 to treat CLN3 disease;...
Analyst Forecast
According to 4 analyst ratings, the average rating for ABEO stock is "Buy." The 12-month stock price forecast is $17, which is an increase of 251.24% from the latest price.
Stock ForecastsNext Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
2 months ago · seekingalpha.com
Abeona Therapeutics: Despite Some Competitive Pressure, This Looks UndervaluedAbeona Therapeutics Inc.'s lead program, pz-cel, is an autologous gene therapy for RDEB, showing significant wound healing and pain reduction in clinical trials. Despite a CRL from the FDA, Abeona res...